Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A RNS to confirm that data collection has completed would be nice, that would help move the SP in the right direction.
Reading through the attachment - last enrolment is 7th MY and last data collection is 4th June so she will be a need to conclude and review before and results, I would have though this would take a few weeks before any valuation, with a following wind end of June 24.
There was an undisclosed buy at 15.26pm or 15.36pm.
Not overly sure how long monitoring of clinical trial patients go on for after cessation of dosage.
Link below regards to trial in Oz. Posted by HbD before l believe.
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12623000416695
It may well be traders anticipating a RNS today and took a gamble that hasn't paid off.
Well....since 11:30 its been almost uninterrupted sells. Certainly making it easier for MMs to walk this back down if they want to
Badsterman, Sareum have always been watertight with regards to leaking information.
We now have other entities involved.
Sareum will be up to date with progress but cannot realistically release any info until full data analysis is completed by the clinical trial organisation and compliance with regulatory control.
If not good then we are indeed well and truly screwed.
Thoughts on MAD timelines Sog If working on 32 weeks for the 4 cohorts that would of been before 15th April coming up 6 + weeks over unless they pulled in a 5th cohort or finances delayed things in oz...
I'm rather hoping the efficient Oz safety committee can deliver (at least some preliminary data), before Sareum head to Bio 24 on June 3rd.
What a fantastic audience for a positive trial result.
However, my hopes usually get incinerated on the pyre known as AIM.
🤪
In effect there exists 2 areas of news here.
Firstly we have satisfactory safety data allowing SDC1801 to progress to further/later stage trials.
Secondly, we can have detailed feedback on how good the safety data is.
Example 1, Drug has exhibited minimal serious adverse events at doses received in healthy patients. Drug considered satisfactory to progress to later stage of trial.
Example2. Drug administered to healthy volunteers exhibited no Indications of any serious adverse events up to the maximum dose authorised by the trial. Drug considered satisfactory to progress to later stage.
There exists a trade off, as dosing increases so does the risk of adverse events increase.
In the first example to achieve a therapeutically effective dose, the dose when significantly increased is likely to exhibit a significant number of events that prevent dosaging at this level.
This most likely to materialise in phase2 studies where around 2 out of 3 drugs statistically fail.
The 2nd example that gave no indication of any adverse events, can and may have a therapeutic dose increased to give an acceptable level of efficacy with little to no detriment with regards to adverse events.
You should be able to see the advantages of the 2nd example.
In addition there will be if course biomarker and other data indicating areas most likely to benefit from SDC1801. Also a knock on effect as to likelihood of a satisfactory out come on SDC1802.
We may prove highly favourable in SLE where others have failed dismally
'250 Pages Report] The systemic lupus erythematosus (SLE) drugs market is projected to record a CAGR of 5% during the forecast period, up from US$ 183.3 Billion in 2020, to reach a valuation of US$ 329.18 Billion by 2032.'
I will add that Small molecule kinase inhibitors in this area are very seriously being investigated.
Regards
Honestly, the first few weeks to months of this trial were sweaty af. I hazard a guess we are well past the point of adverse news.
Disagree, i dont think anything is priced in, quite simply the SP isnt being shackled by RF anymore
That is a very simplistic view Daniel. Firstly, the BoD “expect” so not confirmed at all. Secondly, confirmation will come from the Safety Review Committee in Oz and is independent verification. The analysis of the data may also provide a lot more insight into what we have. Thirdly, we would have successfully negotiated a trial and will attract the attention of bigger players. Finally, it is the end of the working week in Oz tonight and another week passes with no adverse news. I would think there will be a lot of interest in the permutations that open up for Sareum in the coming months
Why would we see a triple digit increase if the news confirms what the BOD have already said?
I'd love to see one, but I can't see it happening. BOD say results expected to be satisfactory. Confirmation they're satisfactory will move things a bit, but the bulk of that news must already be priced in.
The bod have previously indicated that the impending results expect to be satisfactory so there should be some buying momentum here in anticipation.
Considering the lowly SP a triple digit increase could be on the cards imo once the news is hot off the press.
A revised broker note at that point would help the cause.
All to play for over the next 6 weeks.
I agree. Just a feeling that something good is brewing but absolutely no evidence to support that feeling!
It is amusing how when the MMs need some shares they drop the price to make some people panic sell and then put it back up again. Sneaky little buggers. Gla x
Lazarus2, it is indeed unusually quiet on here today in terms of trades and discussion. Hopefully the RNS is being uploaded for release and those in the know are actually going to give us the good news! GLA!!
Cheers for the reply sadoldgit
Weird goings on - no sells/no buys and dummy sell shows no deal available. Something definitely going on. No RNS. Anybody any suggestions?
As for topping the leader board that will happen on RNS of data results.
Regards
From memory around 850 million this pre consolidation of course.
In some respects we are are much further forward.
Chk1 we could do with an update.
1802 needs progressing via informing us as to which cancer Indication or Indications to head for in clinical trials
Aurora FLT3 was fine in preclinical but problems arose due to solubility issues Regarding the oral route.
Basically shelved to concentrate funds on 1801 and 1802.
Pharmaceuticals have taken a hammering since early 2022.
Any manufactures of military equipment have made slow but continuous gains.
World spend on military production this year predicted to exceed 2.6 trillion dollars.
Look.at companies such as BAE systems and Rolls Royce.
As you are aware we await data results confirming satisfactory results that will enable access to phase 2 trials.
At this point or thereabouts can expect on licence or maybe takeover fubjest to CHK1 developments.
Data for 1801 also important for follow on of 1802
Sareum BoD ideally need inform us of what and how they intend to progress following completion of trial data analysis.
Regards
I sold my entire (small) Shanta holding just before the vote results were out NAVMike (as had a feeling we'd get shafted) and chucked it all in here at the last raise.
So far its paid off well on that tranche (but still down 64.72% overall on my entire holding)
Our time in the sun is coming soon (hopefully!)
Cheers sadoldgit.
how many shares where in issue back in 2011.
It was a pound a share prior to RF helping us out with equity share release.
Similar antics still being played, but much less effective to suppress SP in my opinion.
Feb 2011 and a 700% increase on half decent RNS
How many companies achieved that?
Yes of course we have the knock knock Sareum.BoD.
Oddly enough they have contributed nothing of any ubstance or value to this chat board. A couple of them reside over at ADVN.
Regards